Enhancing the Effects of Anti-Cancer Drug ICRF-193

31 Jan 2019
Nicoletta Lanese

Casein kinase II (CKII) phosphorylates DNA topoisomerase II (topo II), thus activating the ATPase domain of the enzyme (left). This activation cancels the effects of anti-cancer drug ICRF-193. If CKII activity is attenuated (right), the efficacy of ICRF-193 is rescued. The G0 Cell Unit demonstrated this mechanism in fission yeast, a simple model that could be used for anti-cancer drug screening. 

Free for anyone to re-use, but must be credited to OIST.
This work is licensed under a Creative Commons Attribution 2.0 Generic License.

Download full-resolution image

Subscribe to Newsletters